Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Public ClinicalTrials.gov record NCT03387020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and everolimus may work better at treating malignant brain tumors.
Study identification
- NCT ID
- NCT03387020
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- Everolimus Drug
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Ribociclib Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2018 (Actual)
- Primary completion
- Apr 1, 2020 (Actual)
- Completion
- Apr 1, 2020 (Actual)
- Last update posted
- Aug 27, 2021
2018 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | 90026 | — |
| Lucile Packard Children Hospital Stanford University | Palo Alto | California | 94304 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| National Cancer Institute Pediatric Oncology Branch | Bethesda | Maryland | 20892 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cincinnati Children Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Children Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| Pediatric Brain Tumor Consortium | Memphis | Tennessee | 38105 | — |
| St. Jude Children Research Hospital | Memphis | Tennessee | 38105 | — |
| Texas Children's Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03387020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03387020 live on ClinicalTrials.gov.